Innovation in Immunology

CoImmune® is a privately held, clinical stage immuno-oncology company that will redefine cancer treatment using best-in-class cellular immunotherapies. Our allogeneic CAR-CIK technology platform for liquid and solid tumors is a variation on CAR-T therapy that promises enhanced efficacy with greatly reduced toxicity. Our autologous RNA-loaded dendritic cell technology for solid tumors uses amplified total tumor mRNA to program highly engineered dendritic cells to generate immune responses against neoantigens without the need to identify them.
Learn More
CMN-001
How does our DC based technology activate your immune response?
More...
Armored CAR CIK
Armored Chimeric Antigen Receptor (CAR) modified Cytokine Induced Killer (CIK) cells.
Learn more
CAR-CIK
Coimmune’s CAR-CIK immunotherapy platform distinguishes itself in three key ways from other CAR-T approaches.
More...
Previous
Next
0
Studies
0
Patents
0
Employees
0
Countries
Our Story

About Us

CoImmune®Inc. is a US company based in Durham North Carolina that was founded in 2019 based on its expertise in the development and manufacture of cell-based therapeutics to treat unmet medical needs including cancer, autoimmune and inflammatory diseases. CoImmune has a 20,000 sq. ft. cGMP manufacturing facility capable of supporting clinical studies from Phase 1 through Phase 3. The company is preparing to initiate its first Phase 2 clinical trial using a strategic combination of immuno-oncology therapeutics.

“All of us at CoImmune are very excited by the work we are doing with our colleagues in Italy. We are planning additional clinical trials to be conducted in the United States and Italy targeting B-ALL, chronic lymphocytic leukemia, non-Hodgkin’s lymphoma and acute myelogenous leukemia”

Charles A. Nicolette

CEO of coIMMUNE

News

Recent Press Releases

  • Frontiers in Immunology

    The Past, Present, and Future of Non-Viral CAR T Cells

    Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology that has revolutionized the way we conceive immunotherapy. The impressive clinical results of complete and prolonged response in refractory and relapsed diseases have shifted the landscape of treatment for hematological malignancies, particularly those of lymphoid origin, and opens up new possibilities for the treatment of solid neoplasms. However, the widening use of cell therapy is hampered by the accessibility to viral vectors that are commonly used for T cell transfection.

  • Sloan Kettering Institute

    Sloan Kettering Institute Scientists Retool CAR T Cells to Serve as ‘Micropharmacies’ for Cancer Drugs

Our Products

Technology

Focused on the development and commercialization of our clinical-stage platform technologies

CAR-CIK

allogeneic CAR-CIK cells

Solid Tumors

allogeneic CAR-CIK in solid tumors

CMN-001

autologous RNA-loaded dendritic cells

coimmune-text-only-r
4233 Technology Drive | Durham NC 27704 | 919-287-6300
Linkedin-in Twitter
©2022 cōIMMUNE® | All rights reserved